Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
05/16/2012 | 11:11am CET

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
03/17JOHNSON & JOHNSON : FDA Breakthrough Therapy Designation for Erdafitinib in the ..
03/17JOHNSON & JOHNSON : Platinum Equity Submits Binding Offer to Acquire LifeScan Fr..
03/16JOHNSON & JOHNSON : J&J nears diabetes device exit with $2.1 bln LifeScan sale
03/16JOHNSON & JOHNSON : nears diabetes device exit with $2.1 billion LifeScan sale
03/16JOHNSON & JOHNSON : Janssen Announces U.S. FDA Breakthrough Therapy Designation ..
03/16JOHNSON & JOHNSON : Platinum Equity Submits Binding Offer to Acquire LifeScan Fr..
03/16JOHNSON & JOHNSON : Announces Binding Offer from Platinum Equity to Acquire Life..
03/16JOHNSON & JOHNSON : Mylan propose ways to cut TB drugs prices in India
03/15JOHNSON & JOHNSON : - New Late-Breaking Study Finds Wearable Electrocardiogram M..
03/15JOHNSON & JOHNSON : - INVOKANA Significantly Reduces the Risk of Heart Failure-R..
More news
News from SeekingAlpha
03/18Basic Guide To Successful Investing - Part I 
03/183 THINGS IN BIOTECH, MARCH 17 : Janssen's Bladder Breakthrough, MorphoSys' Alzhe.. 
03/17JOHNSON & JOHNSON : A Dividend King For Strong Returns 
03/17RETIRE RICH : How To Buy Low And Sell High 
03/16COCA-COLA : Dividend King But With Poor Total Return 
Financials ($)
Sales 2018 81 115 M
EBIT 2018 24 940 M
Net income 2018 19 683 M
Debt 2018 12 439 M
Yield 2018 2,70%
P/E ratio 2018 18,56
P/E ratio 2019 17,42
EV / Sales 2018 4,57x
EV / Sales 2019 4,23x
Capitalization 359 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 150 $
Spread / Average Target 12%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-4.77%358 615
PFIZER0.99%218 946
NOVARTIS-5.34%216 150
ROCHE HOLDING LTD.-10.73%201 801
MERCK AND COMPANY-1.07%148 965
AMGEN8.25%136 727